Drug Type Recombinant polypeptide, Biosimilar |
Synonyms- |
Target |
Mechanism PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants, Parathyroid hormone replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (16 Nov 2023), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | US | 16 Nov 2023 |